Biomarkers in Phase I-II Chemoprevention Trials: Lessons from the NCI Experience

Overview

Journal Ecancermedicalscience

Specialty Oncology

Date 2015 Dec 5

PMID 26635903

Citations 2

Authors

Eva Szabo

Affiliations

Soon will be listed here.

Abstract

Early phase clinical trials are an essential component of chemopreventive drug development to identify signals of drug efficacy that can subsequently be explored definitively in phase III trials. Whereas phase I trials focus on safety and identification of optimal dose and schedule for cancer prevention, phase II trials focus on intermediate endpoints that are variably related to cancer development. The United States National Cancer Institute supports a programme devoted to early phase cancer prevention clinical trials. The experience, along with the benefits and limitations of the range of biomarker endpoints used in these studies, are reviewed here.

Citing Articles

A Systematic Review and Pooled Analysis of Hypothesized versus Observed Effect Sizes in Early Phase Cancer Prevention Clinical Trials.

Eickhoff J, Zaborek J, Chen G, Sahasrabuddhe V, Ford L, Szabo E Cancer Prev Res (Phila). 2023; 16(8):471-478.

PMID: 37258421 PMC: 10527540. DOI: 10.1158/1940-6207.CAPR-23-0060.

Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer.

Samimi G, Heckman-Stoddard B, Kay S, Bloodgood B, Coa K, Robinson J Cancer Prev Res (Phila). 2019; 12(4):271-282.

PMID: 30824471 PMC: 6445710. DOI: 10.1158/1940-6207.CAPR-18-0435.

References

Pinsky P, Nath P, Gierada D, Sonavane S, Szabo E . Short- and long-term lung cancer risk associated with noncalcified nodules observed on low-dose CT. Cancer Prev Res (Phila). 2014; 7(12):1179-85. PMC: 4206664. DOI: 10.1158/1940-6207.CAPR-13-0438. View

Li T, Kung H, Mack P, Gandara D . Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013; 31(8):1039-49. PMC: 3589700. DOI: 10.1200/JCO.2012.45.3753. View

Kelloff G, Lippman S, Dannenberg A, Sigman C, Pearce H, Reid B . Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006; 12(12):3661-97. DOI: 10.1158/1078-0432.CCR-06-1104. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Lam S, Leriche J, McWilliams A, MacAulay C, Dyachkova Y, Szabo E . A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004; 10(19):6502-11. DOI: 10.1158/1078-0432.CCR-04-0686. View

Veronesi G, Lazzeroni M, Szabo E, Brown P, DeCensi A, Guerrieri-Gonzaga A . Long-term effects of inhaled budesonide on screening-detected lung nodules. Ann Oncol. 2015; 26(5):1025-1030. PMC: 4405280. DOI: 10.1093/annonc/mdv064. View

Messing E, Gee J, Saltzstein D, Kim K, diSantAgnese A, Kolesar J . A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila). 2012; 5(4):621-30. PMC: 3324663. DOI: 10.1158/1940-6207.CAPR-11-0455. View

Saccomanno G, Archer V, AUERBACH O, Saunders R, Brennan L . Development of carcinoma of the lung as reflected in exfoliated cells. Cancer. 1974; 33(1):256-70. DOI: 10.1002/1097-0142(197401)33:1<256::aid-cncr2820330139>3.0.co;2-g. View

Gustafson A, Soldi R, Anderlind C, Scholand M, Qian J, Zhang X . Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med. 2010; 2(26):26ra25. PMC: 3694402. DOI: 10.1126/scitranslmed.3000251. View

10.

Mehanna H, Rattay T, Smith J, McConkey C . Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck. 2009; 31(12):1600-9. DOI: 10.1002/hed.21131. View

11.

Lee J, Hong W, Hittelman W, Mao L, Lotan R, Shin D . Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000; 6(5):1702-10. View

12.

Bertagnolli M, Eagle C, Zauber A, Redston M, Solomon S, Kim K . Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355(9):873-84. DOI: 10.1056/NEJMoa061355. View

13.

Veronesi G, Szabo E, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D . Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila). 2010; 4(1):34-42. PMC: 3017323. DOI: 10.1158/1940-6207.CAPR-10-0182. View

14.

Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan M . A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast. Clin Cancer Res. 2014; 20(14):3672-82. PMC: 4101910. DOI: 10.1158/1078-0432.CCR-13-3045. View

15.

Ohtsuka T, Watanabe K, Kaji M, Naruke T, Suemasu K . A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur J Cardiothorac Surg. 2006; 30(1):160-3. DOI: 10.1016/j.ejcts.2006.03.058. View

16.

Nakajima R, Yokose T, Kakinuma R, Nagai K, Nishiwaki Y, Ochiai A . Localized pure ground-glass opacity on high-resolution CT: histologic characteristics. J Comput Assist Tomogr. 2002; 26(3):323-9. DOI: 10.1097/00004728-200205000-00001. View

17.

Meyskens Jr F, McLaren C, Pelot D, Fujikawa-Brooks S, Carpenter P, Hawk E . Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008; 1(1):32-8. PMC: 2562024. DOI: 10.1158/1940-6207.CAPR-08-0042. View

18.

Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L . Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr. 2011; 2011(43):120-3. DOI: 10.1093/jncimonographs/lgr034. View